Andy Bertapelle

The board meeting agenda includes an educational segment regarding hospital board responsibilities in clinical measures, alongside reports from commissioner committees. Additionally, an executive session is scheduled to discuss the potential acquisition of real estate as permitted by RCW guidelines.

The agenda includes items such as the approval of the agenda, business from the audience, consent agenda items including special and regular meeting minutes, warrants, vouchers, EFTs, bad debts, and the Healthcare Assistance Program. The CEO and Executive Team/Senior Leadership will provide reports. The board will convene the 2026 Operating and Capital Budget Hearing, review the proposed budget including taxation requirements, and allow public comment. The board will also discuss and potentially adopt the 2026 Operating and Capital Budget, cancel warrants, declare a surplus of assets, and adopt an updated Mission/Vision and 2026-2028 Strategic Plan.

The special board meeting included an open public comment session regarding CEO succession, where guests emphasized the importance of vetting a qualified candidate with a character that fits the team and who will collaborate with other healthcare providers. The board discussed the CEO succession planning process, including the appointment of Holly Stanley, CFO, and Chris Wagar, COO, as interim co-CEOs, with Chris Wagar also serving as the District Superintendent. The board convened in executive session. The board accepted CEO John White's resignation and directed the Board Chair and Superintendent to draft a resolution for the appointment and compensation of the interim co-CEOs and the District Superintendent.

The meeting included updates from various departments including Radiology, Co-CEO, CFO, Quality, CMO, and Chief of Medical Staff. The board discussed the CEO Transition, the introduction of the 2025 Operating and Capital Budget and Taxation into Records of Commission for Public Inspection, and Resolution 692 regarding the Surplus of Personal Property. An executive session was held concerning matters of litigation.

The meeting included a presentation and analysis of the 2023 Financial Statement, a discussion and approval of the Scope of Authority Policy, and continued discussion regarding CEO transition planning. The board approved increasing the Chief Medical Officer position to full-time and adopted resolutions concerning surplus property and designating an officer to co-sign warrants. The 2023 District Audited Financial Statements were accepted. Staff reports were presented, covering CEO activities, financial status, operations, nursing, human resources, quality and patient experience, marketing, and CMO activities. The meeting also involved an executive session to discuss matters of litigation, quality improvement, and evaluation of qualifications for public employment.